drugset / Trial / NCT05576077
A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A multicenter trial to investigate TBio-4101, an autologous, neoantigen-selected, tumor-reactive TIL product, in patients with advanced solid malignancies.
Timeline
- Start
- 2023-01-17
- Primary completion
- 2025-02-04
- Completion
- 2025-02-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | Tumor Infiltrating Lymphocytes | Cell therapy | — | — |